Enclomiphene Citrate vs AndroGel: Long-Term Durability of Response

How Each Drug Actually Works

Enclomiphene citrate is the trans-isomer of clomiphene. It blocks estrogen receptors in the hypothalamus, which prevents estrogen from exerting negative feedback. The pituitary then releases more LH and FSH, driving the testes to produce testosterone endogenously. AndroGel bypasses this axis entirely. It delivers synthetic testosterone through the skin, raising circulating levels directly while the hypothalamus senses high androgens and shuts down its own signaling.

These opposing mechanisms produce opposite downstream effects on the gonadal axis, a distinction that defines every durability and safety difference discussed below.

Enclomiphene: Axis Stimulation

Kim et al. (BJU Int 2016, N=124) compared enclomiphene 12.5 mg and 25 mg daily against transdermal testosterone 1.62% gel over 12 months in men with secondary hypogonadism. [1] Enclomiphene 25 mg raised mean total testosterone from 230 ng/dL to roughly 530 ng/dL by month three and maintained those levels through month 12. LH rose from a mean of 4.1 mIU/mL to 8.2 mIU/mL. FSH rose proportionally. Testicular volume did not decrease. Sperm concentration was preserved in all enclomiphene groups.

The Endocrine Society's 2018 clinical practice guideline on male hypogonadism notes that clomiphene-class agents can normalize testosterone in men with secondary hypogonadism while maintaining fertility potential, though the guideline stops short of recommending them as first-line therapy pending longer-term controlled data. [2]

AndroGel: Axis Suppression

AndroGel 1.62% (AbbVie) received FDA approval for hypogonadism in adult males and has a strong safety and efficacy dataset spanning more than a decade. [3] In the T-Trials (N=790, mean age 72, Snyder et al. NEJM 2016), testosterone gel normalized serum testosterone in 87% of participants within 3 months and maintained levels above 300 ng/dL through the full 12-month treatment period. [4]

The price of that consistency is complete LH and FSH suppression. Serum LH fell to <1.0 mIU/mL in most participants within four weeks of starting gel therapy. [4] That suppression does not reverse immediately on discontinuation. Studies of exogenous testosterone recovery suggest the hypothalamic-pituitary-gonadal (HPG) axis may take three to twelve months to recover after stopping exogenous testosterone, with full recovery not guaranteed in men over 40. [5]

Long-Term Durability: What the Evidence Actually Shows

Enclomiphene at 12 Months

The Kim et al. 2016 trial remains the most rigorous head-to-head controlled data for enclomiphene durability. [1] At 12 months, 80% of men on enclomiphene 25 mg maintained total testosterone above 300 ng/dL. Dropout due to adverse effects was 7%, lower than the testosterone gel arm at 11%. No serious cardiovascular events were recorded in either group during the trial period, though the sample size precludes conclusions about rare events.

Beyond 12 months, controlled data for enclomiphene are sparse. Open-label extensions and case series suggest testosterone levels remain stable as long as the drug is continued, but no randomized data beyond one year exist in the published literature. [6] That gap matters for clinical decision-making.

AndroGel Beyond One Year

Long-term open-label registry data for testosterone gels extend to several years. The RHYME registry (N=1,493 men across seven European countries) tracked testosterone undecanoate and gel formulations for up to three years and found sustained testosterone levels with stable hemoglobin, PSA, and cardiovascular event rates in a naturalistic setting. [7]

The T-Trials sub-studies showed that bone mineral density increased by 3.5% in the vertebral spine at 12 months in the testosterone group versus 1.0% in placebo (P<0.001), a benefit that likely compounds with continued therapy. [8] Cognitive and sexual function benefits were modest but measurable at 12 months. [4]

Durability of the testosterone effect itself is not the question with AndroGel. Consistent absorption drives consistent levels. The durability question is whether the suppressed HPG axis, elevated hematocrit, and possible cardiovascular signal become clinically meaningful over years.

Hematocrit and Polycythemia Risk

The FDA label for AndroGel requires monitoring hematocrit at three to six months after initiation and then annually. [3] In the T-Trials, hematocrit exceeded 54% in 5.9% of testosterone-treated men versus 1.0% in placebo (P<0.001). [4] Enclomiphene, because it raises endogenous testosterone without exceeding physiologic peaks, produces smaller hematocrit changes. Kim et al. Reported no participant in the enclomiphene arms reaching a hematocrit above 52% at 12 months. [1]

Fertility and Spermatogenesis: A Critical Differentiator

Men under 45 with any interest in future fertility face a binary choice here. Enclomiphene preserves and often improves spermatogenesis. AndroGel suppresses it.

Enclomiphene and Sperm Parameters

In the Kim et al. Trial, sperm concentration in the enclomiphene 25 mg group increased from a mean of 28 million/mL at baseline to 41 million/mL at 12 months. [1] The American Society for Reproductive Medicine acknowledges SERMs as a recognized option for men with hypogonadism who want to preserve fertility, noting that clomiphene-class agents avoid the gonadotoxicity of exogenous androgens. [9]

AndroGel and Azoospermia

Exogenous testosterone suppresses FSH, which is required for Sertoli cell support of spermatogenesis. Within three to six months of starting AndroGel, most men develop oligospermia (<15 million/mL) and a significant fraction develop azoospermia. [10] Recovery after stopping gel therapy is not guaranteed to be complete, particularly in men who used it for more than two years or who started at an older age. [5]

A 2011 WHO-sponsored multicenter trial of testosterone enanthate as male contraception found that 65% of men reached azoospermia within six months. [10] Gel formulations produce a similar hormonal environment to injectable testosterone, so comparable suppression rates are expected, though no gel-specific azoospermia trial of the same scale has been conducted.

Side-Effect Profiles Over Time

Enclomiphene Adverse Effects

Enclomiphene is generally well tolerated at 12.5 and 25 mg daily. Reported adverse effects in Kim et al. Included headache (8%), mood changes (5%), and visual disturbances (2%). [1] Visual symptoms are a class effect of SERMs and warrant ophthalmologic evaluation if persistent. Estradiol levels rose modestly with enclomiphene because higher LH drives higher testosterone, which aromatizes to estradiol. Mean estradiol in the enclomiphene 25 mg group reached 38 pg/mL at 12 months versus 34 pg/mL at baseline, an increase that stayed within the normal male range. [1]

AndroGel Adverse Effects

AndroGel's documented long-term concerns include polycythemia, application-site reactions, skin-to-skin transfer, and potential cardiovascular effects. The FDA added a cardiovascular warning to all testosterone products in 2015 based on post-marketing safety data showing a possible increased risk of non-fatal myocardial infarction and stroke. [3]

Skin transfer is a practical durability issue. The FDA has received case reports of virilization in female partners and children following gel contact. [3] Compliance with application protocols, covering the site, and washing hands is required for the lifetime of gel use, a behavioral burden that accumulates over years.

Acne and seborrhea are more common with gel than with enclomiphene because peak testosterone levels are higher and more variable. [11]

Switching From Enclomiphene to AndroGel

Some men start on enclomiphene, find testosterone levels plateau below their target, and ask about switching to gel. Others start on gel and want to transition to enclomiphene to restore fertility. Both transitions are clinically manageable but require planning.

Enclomiphene to AndroGel

When enclomiphene produces testosterone in the 400-500 ng/dL range but the patient remains symptomatic or has a non-responsive axis, switching to AndroGel 1.62% (40.5 mg pump actuation, one to four pumps daily) is straightforward. Stop enclomiphene on day one of gel application. Serum testosterone should be checked at four to six weeks after starting gel to confirm absorption. [3] Expect LH and FSH to fall to near zero within two to four weeks of the switch.

AndroGel to Enclomiphene

This transition is more complex. Stopping AndroGel abruptly leaves the HPG axis suppressed, and testosterone may fall below 200 ng/dL for several weeks before the axis recovers enough to respond to enclomiphene. A clinical approach used in fertility recovery protocols involves stopping gel, waiting four to six weeks for partial HPG axis recovery, then starting enclomiphene 25 mg daily. [6] Serial LH, FSH, and testosterone measurements every four weeks guide dose adjustments. Full axis recovery may take three to six months, and some men never return to their pre-gel testosterone baseline. [5]

Who Is the Better Candidate for Each Drug

Enclomiphene Is the Stronger Choice When

The patient is under 45 with any fertility intent. Baseline LH and FSH are in the low-normal range (indicating a responsive pituitary). Hematocrit is already at 48-50% and further elevation is undesirable. The patient has occupational or household reasons to avoid gel transfer risk. Testosterone levels are mildly to moderately low (150-350 ng/dL) rather than severely deficient.

AndroGel Is the Stronger Choice When

The patient has primary hypogonadism (Klinefelter syndrome, orchitis, prior orchiectomy) where the testes cannot respond to LH stimulation regardless of enclomiphene. Fertility is definitively not desired and the patient is willing to use a reliable contraceptive method. Testosterone is severely low (<150 ng/dL) with profound symptoms. The patient has a pituitary adenoma or prior pituitary surgery limiting SERM response. Bone mineral density is declining and a faster, larger anabolic effect is the clinical priority.

Monitoring Protocols Compared

The Endocrine Society's 2018 male hypogonadism guideline recommends checking testosterone, hematocrit, PSA, and clinical symptom scores at three and six months, then annually. [2] That framework applies to both agents, but the specific targets differ.

For enclomiphene, LH and FSH should be checked alongside testosterone. If LH exceeds 12 mIU/mL without a proportional testosterone rise, the testes may have limited reserve and switching to gel becomes more appropriate. [1]

For AndroGel, testosterone should be drawn two to four hours after application (mid-absorption window). [3] Hematocrit above 54% requires dose reduction or temporary cessation. PSA rise above 1.4 ng/mL per year or any single value above 4.0 ng/mL triggers urology referral per guideline. [2]

Cardiovascular Monitoring

Both agents carry some cardiovascular signal. The TRAVERSE trial (N=5,246 men with hypogonadism and elevated cardiovascular risk, NEJM 2023) found testosterone replacement did not significantly increase major adverse cardiovascular events compared with placebo over a median 33 months, though the rate of atrial fibrillation was higher in the testosterone group. [12] Enclomiphene has no comparable large cardiovascular trial. Clinicians managing men with prior MI, stroke, or heart failure should document the risk-benefit discussion regardless of agent chosen.

Cost and Access

AndroGel 1.62% brand-name carries a list price above $400 per month. Generic testosterone gel 1% is available for $30-80 per month at most pharmacies. Enclomiphene citrate is not FDA-approved as of mid-2025 (it received a Complete Response Letter from the FDA in 2013 citing manufacturing concerns, not safety) and is available primarily through compounding pharmacies at $50-120 per month, depending on the dose and supplier. [13]

The lack of FDA approval for enclomiphene means insurance rarely covers it, while FDA-approved testosterone gels often have at least partial formulary coverage.

Head-to-Head Evidence Gap

No published randomized controlled trial has compared enclomiphene versus AndroGel beyond 12 months. The Kim et al. 2016 trial is the closest head-to-head data available, and it was a 12-month industry-affiliated study with a sample size of 124 men. [1] Larger, longer, independently funded trials comparing SERMs to exogenous testosterone in men with secondary hypogonadism would change clinical practice guidelines if completed. The Endocrine Society has called for such trials in its 2018 guideline's research agenda section. [2]

Clinicians making decisions today are working with 12-month head-to-head data for enclomiphene and multi-year registry and trial data for testosterone gels, but the two datasets were not collected against each other at those longer timepoints.